Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of HLX10 plus chemotherapy, HLX10 + HLX04 plus chemotherapy, versus chemotherapy in advanced non-squamous non-small cell lung cancer
CTR20191044Phase 3Completed
- Sponsor
- HyBioPharma
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab, HLX04-O, carboplatin, pemetrexed in Non-small cell lung cancer (NS-NSCLC), sponsored by HyBioPharma. Started Dec 2019; status: completed.
02
Drugs
serplulimabHLX04-Ocarboplatinpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20191044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191044.